Book Read Free

When the Wolves Bite

Page 25

by Scott Wapner

30. Office of Massachusetts Senator Edward J. Markey, Official Press Release.

  31. Stuart Pfeifer, “US Senator Calls for Investigation of Herbalife; Shares Tumble,” Los Angeles Times, January 23, 2014.

  32. William Alden, “A Year Later, Ackman Sticks with His Bet Against Herbalife,” New York Times, February 13, 2014.

  33. CNBC, Power Lunch, March 12, 2014.

  34. Nathan Vardi, “FTC Launches Herbalife Inquiry, Shares Fall,” Forbes, March 12, 2014.

  Chapter 12: The Death Blow

  1. Dan McCrum and Kara Scannell, “Criminal Probe Launched into Herbalife,” Financial Times, April 11, 2014.

  2. Stuart Pfeifer and Richard A. Serrano, “Federal Investigation Target L.A. -based Herbalife,” Los Angeles Times, April 11, 2014.

  3. Emily Flitter and Svea Herbst-Bayliss, “FBI Conducting a Probe into Herbalife: Sources,” Reuters, April 11, 2014.

  4. CNBC and Institutional Investor, Delivering Alpha, The Pierre Hotel, July 16, 2016.

  5. Matthew Goldstein and Alexandra Stevenson, “Icahn and Ackman Publicly End Feud with an Embrace,” New York Times, July 16, 2016.

  6. Julia LaRoche, “Bill Ackman Is About to Unveil the Most Important Presentation of His Career,” Business Insider, July 21, 2014.

  7. CNBC, Fast Money: Halftime Report, July 21, 2014.

  8. Betting on Zero, Zipper Brother’s Films, Gunpowder & Sky, Ted Braun, 2016.

  9. Ibid.

  10. Ibid.

  11. Ibid.

  12. CNBC, Squawk on the Street, July 21, 2014.

  13. Ibid.

  14. Betting on Zero.

  15. Ibid.

  16. Ibid.

  17. Ibid.

  18. Ibid.

  19. Max Nisen, “Bill Ackman Just Enriched a Man He Loathes with His Failed Herbalife ‘Death Blow,’” Quartz, July 23, 2014.

  20. Betting on Zero.

  21. Jonathan Berr, “Herbalife Wins a Round Against Bill Ackman,” CBS Money Watch, July 22, 2014.

  22. Herbalife Earnings Call Transcript, July 28, 2014.

  23. Herbalife Earnings Call Transcript, November 4, 2014.

  24. Ibid.

  25. Ibid.

  26. Ibid.

  27. Letter to Investors, Pershing Square Capital Management, November 25, 2014.

  28. Ibid.

  29. Top 20 Hedge Funds, LCH Investments.

  30. Svea Herbst-Bayliss, “Exclusive: Ackman’s Pershing Square Makes $3.3 Billion Bet on Valeant,” Reuters, March 9, 2015.

  Chapter 13: The Year That Wasn’t

  1. Nathan Vardi, “Bill Ackman Wins 2014,” Forbes, November 17, 2014.

  2. Jordan Walthen, “Bill Ackman, Pershing Square Deliver Legendary Performance,” USA Today, October 4, 2015.

  3. Christopher M. Matthews, “Prosecutors Interview People Tied to Ackman in Probe on Potential Herbalife Manipulation,” Wall Street Journal, March 12, 2015.

  4. CNBC, Fast Money: Halftime Report, March 13, 2015.

  5. Michelle Celarier, “Herbalife Hires New Crisis PR Firm to Fight Ackman,” New York Post, January 8, 2015.

  6. Matthew J. Belvedere, “Bill Ackman: I Haven’t Traded Around Herbalife Short,” CNBC.com, March 13, 2015, www.cnbc.com/2015/03/13/bill-ackman-no-fbi-doj-contact-over-herbalife.html.

  7. David M. Levitt and Oshrat Carmiel, “Ackman Group Pays $91.5 Million for Condo at NYC’s One57,” Bloomberg, April 10, 2015.

  8. Ibid.

  9. Alexandra Stevenson, “Bill Ackman and His Hedge Fund, Betting Big,” New York Times, October 25, 2014.

  10. Svea Herbst-Bayliss, “Exclusive: Ackman’s Pershing Square Makes $3.3 Billion Bet on Valeant,” Reuters, March 9, 2015.

  11. Nathan Vardi, “Bill Ackman Outs Valeant CEO Mike Pearson as a Billionaire,” Fortune, April 22, 2014.

  12. Devin Leonard and Caroline Chen, “Valeant’s Boss Is Back: Can the CEO Save the Day, Again?” Bloomberg, March 3, 2016.

  13. Allergan News Release, “Allergan Files Lawsuit in Federal Court Against Valeant and Pershing Square for Violations of Federal Securities Laws,” August 1, 2014.

  14. Investment Master Class, “Lessons from Valeant,” April 8, 2017.

  15. William D. Cohan, “In Allergan Bid, a Question of Insider Trading,” New York Times, April 23, 2014.

  16. CNBC, Squawk Box, April 23, 2014.

  17. Cohan, “In Allergan Bid.”

  18. CNBC, Halftime Report, July 21, 2014.

  19. CNBC, Squawk Box, June 9, 2014.

  20. Ed Hammond, Scott Deveau, and Doni Bloomfield, “Drugmaker Valeant to Buy Salix in Deal Worth About $14.5 Billion,” February 22, 2015.

  21. CNBC, Squawk on the Street, February 24, 2015.

  22. Jen Wieczner, “Bill Ackman: Valeant Could Be the Next Berkshire Hathaway,” Fortune, May 4, 2015.

  23. Gretchen Morgenson and Geraldine Fabrikant, “Hedge Fund Titan’s Surefire Bet Turns into a $4 Billion Loss,” New York Times, March 19, 2017.

  24. Andrew Pollack and Sabrina Tavernise, “Valeant’s Drug Price Strategy Enriches It, but Infuriates Patients and Lawmakers,” New York Times, October 4, 2015.

  25. Roberth Langreth and Drew Armstrong, “Clinton’s Tweet on High Drug Prices Sends Biotech Stocks Down,” Bloomberg, September 21, 2015.

  26. Pollack and Tavernise, “Valeant’s Drug Price Strategy Enriches It.”

  27. Jennifer Ablan, “Valeant’s Crisis Fuels Feud Between Ackman and Australian Fund Manager Hempton,” Reuters, November 3, 2015.

  28. Roddy Boyd, “The King’s Gambit: Valeant’s Big Secret,” Southern Investigative Reporting Foundation, October 19, 2015.

  29. Andrew Pollack, “Drug Makers Sidestep Barriers on Pricing,” New York Times, October 19, 2015.

  30. Daniel Bases, Ryan Vlastelica, Claire Baldwin, and Mark Bendeich, “Special Report: The ‘Shorts’ Who Popped a China Bubble,” Reuters, August 5, 2011.

  31. Citron Research, “Valeant: Could This Be the Pharmaceutical Enron?,” October 21, 2015.

  32. Myles Udland, “Pharma-Giant Valeant Accused of Fraud, Denies It—Stock Still Craters,” Business Insider, October 21, 2015.

  33. Antoine Gara, “Valeant Plunges 30% After Short-Seller Citron Research Makes Fraud Allegation,” Forbes, October 21, 2015.

  34. Udland, “Pharma-Giant Valeant Accused of Fraud.”

  35. Jonathan D. Rockoff and Jeanne Whalen, “Valeant and Pharmacy More Intertwined Than Thought,” Wall Street Journal, October 25, 2015.

  36. Monica Langley, “Activist Investor Bill Ackman Plays Defense,” Wall Street Journal, November 4, 2015.

  37. Ibid.

  38. Ibid.

  39. Ibid.

  40. Ibid.

  41. Reuters Staff, “Valeant Severs Ties with Controversial Pharmacy Distributor,” October 30, 2015.

  42. Julia La Roche, “Bill Ackman Just Spent 4 Hours Defending His Giant Position in Valeant,” Business Insider, October 30, 2015.

  43. “CNBC Excerpts: CNBC Exclusive: ValueAct CEO Jeffrey Ubben Speaks with CNBC’s Kelly Evans on ‘Closing Bell,’ Today,” CNBC.com, March 14, 2016.

  44. “Herbalife Issues Statement Regarding Bill Ackman’s Presentation,” Business Wire, October 30, 2015.

  45. Gibson Dunn Letter, “Suspicious Trading in Herbalife (HLF) Puts in Advance of June 25, 2015 New York Post Article,” July 20, 2015.

  46. Ben Walsh, “Someone Made a Suspiciously Timed Bet That Herbalife Stock Would Plummet,” Huffington Post, October 16, 2015.

  47. Gibson Dunn Letter, “Suspicious Trading.”

  48. Ed Hammond, “Valeant Hits a Two-Year Low After Ackman’s Presentation,” Bloomberg, October 30, 2015.

  49. Michelle Celarier, “Bill Ackman and Michael Pearson: The Inside Story,” Fortune, March 27, 2016.

  50. Ibid.

  51. Michael Johnson, “Market Manipulation by Hedge Fund Short Seller William Ackman,” personal letter in author’s possession, November 12, 2015.

  52. Ibid.

  53. Svea Herbst-Bayliss, “Ackman Tells
Investors That This Year Could Be His Firm’s Worst Ever,” Reuters, December 16, 2015.

  54. Nathan Vardi, “Billionaire Bill Ackman’s Pershing Square Hedge Fund Is Down 19% in 2015,” Forbes, November 2, 2015.

  55. Reuters Staff, “Bill Ackman Says His Fund Is Having Its Worst Year Ever,” Fortune, December 16, 2015.

  56. Federal Trade Commission Press Release, “FTC Acts to Halt Vemma as Alleged Pyramid Scheme,” August 26, 2015.

  57. Pershing Square Capital Management Letter to Investors, December 15, 2015.

  58. Reuters, “Icahn Takes Stake in Cheniere Energy, Seeks Board Seat,” August 6, 2015.

  59. Maureen Farrell, “Apple Stock Plunges 12%,” CNN Money, January 24, 2013.

  60. Ibid.

  61. Adrian Covert, “Apple Shares Soar on Increased Buyback,” CNN Tech, April 24, 2014.

  62. Jennifer Booton, “Apple Spent $56 Billion on Buybacks in 2014,” MarketWatch, December 26, 2014.

  63. Stephanie Yang, CNBC’s Trading Nation, December 21, 2015.

  Chapter 14: The Flush and the Feds

  1. Ackman email to FTC Chairwoman Ramirez, obtained through FOIA Request to Federal Trade Commission. Information delivered on February 23, 2017.

  2. Roger Parloff, “Herbalife in Talks with FTC to Resolve Probe,” Fortune, February 25, 2016.

  3. FTC Complaint, Case Number 2:16-cv-05217

  4. Ibid.

  5. Ibid.

  6. Ibid.

  7. Ibid.

  8. Ibid.

  9. Ibid.

  10. CNBC, Fast Money: Halftime Report, March 1, 2016.

  11. Linda A. Johnson, “Valeant’s Stock Loses Half Its Value,” US News and World Report, March 15, 2016.

  12. Letter to Investors, Pershing Square Capital Management, March 15, 2016.

  13. Jen Wieczner, “Valeant CEO Promises Company Won’t Go Bankrupt in Staff Memo,” Fortune, March 18, 2016.

  14. Letter to Investors, Pershing Square Capital Management, May 11, 2016.

  15. CNBC, Fast Money: Halftime Report, May 2, 2016.

  16. Matthew Townsend, “Herbalife Soars After Saying It’s Close to FTC Resolution,” Bloomberg, May 5, 2016.

  17. Ibid.

  18. Ackman email to FTC Chairwoman Ramirez, obtained through FOIA Request to FTC, May 24, 2016.

  19. Ibid.

  20. Ibid.

  21. Ibid.

  22. Ibid.

  23. FTC Official Press Release Announcing Herbalife Settlement, July 15, 2016.

  24. Ibid.

  25. Herbalife Statement, “Herbalife and the Federal Trade Commission Reach Settlement Agreement,” July 15, 2016.

  26. Kevin McCoy and Nathan Bomey, “Herbalife Agrees to $200M FTC Settlement,” USA Today, July 15, 2016.

  27. Carl Icahn, “Carl Icahn Issues Statement in Response to Herbalife’s Settlement with the FTC,” carlicahn.com, July 15, 2016.

  28. Lindsay Rittenhouse, “Herbalife Settlement Is Profound Victory,” The Street, July 15, 2016.

  Chapter 15: Finale or Fakeout?

  1. Michelle Celarier, “Inside Wall Street’s Greatest Feud,” Fortune, September 19, 2016.

  2. Ibid.

  3. Ibid.

  4. David Benoit, “Carl Icahn Mulled Selling Herbalife Stake to Group That Included Bill Ackman,” Wall Street Journal, August 26, 2016.

  5. CNBC, Squawk Box, August 26, 2016.

  6. Carl Icahn, “Carl Icahn Issues Statement Regarding Herbalife,” carlicahn.com, August 26, 2016.

  7. Letter to Investors, Pershing Square Capital Management, December 7, 2016.

  Coda: Big Thoughts

  1. Alon Brav, Wei Jiang, and Hyunseob Kim, “The Real Effects of Hedge Fund Activism: Productivity, Asset Allocation, and Industry Concentration,” Abstract, p 1.

  INDEX

  AB Electrolux, 120

  Ackman, William A., 1, 2, 10–11, 14–15, 16, 17–18, 21, 22, 31, 64, 69, 70–71, 72–74, 78, 87–88, 96, 98, 99, 100, 111, 130, 134–135, 137, 141–165, 171, 181–182, 189, 199, 201–202

  assets under management, 165, 210

  at AXA Center in 2014, 160–162

  characterized, 17, 22, 23, 24, 25, 75 (see also Ackman, William A.: psychological profile of)

  consumer groups contacted by, 142–143

  at Delivering Alpha conferences, 157, 208

  deposition in May 2003, 32–33

  email to Pearson, 179

  emails to FTC Chairwoman, 189–190, 196–197

  father of, 23, 24, 25, 26, 161

  first stock purchase of, 27

  and FTC settlement, 199, 201

  and Handler, 204–205, 208

  at Harbor Investment Conference, 152

  at Harvard College and Business School, 25–26, 27

  and Icahn, 2, 33–35, 100, 101–109, 113, 114, 147, 157–158, 205, 206, 207–208, 212, 215

  and Johnson, 76–77, 162, 180, 195, 209

  lawsuit against Icahn in 2004, 35

  lobbying of, 141–144, 152, 153

  and Loeb, 88–89, 90, 91

  modified position on Herbalife, 215

  money made for investors by, 165

  money spent on Herbalife campaign, 168

  psychological profile of, 5–9 (see also Ackman, William A.: characterized)

  public persona of, 8

  restructuring Herbalife short position, 148–149

  at Robin Hood Investment Conference, 149–150

  sister Jeanne, 25

  at Sohn special event in 2012, 78–80, 81, 83, 89

  statement to author about Hallwood issue, 102

  taking Pershing Square public, 180

  and Valeant, 174–175, 178, 210

  visit to FTC headquarters, 142

  worst investment of, 40

  See also Pershing Square Capital Management

  Ackman-Ziff real-estate brokerage firm, 24

  Actavis, 170

  activists. See consumer activists; shareholder activists

  Albright, Madeleine, 148

  Alexander’s department store chain, 27

  Allen, Claudia, 38

  Allergan company, 169

  Allied Capital, 62–63

  Allied Financial, 58

  American Airlines, 124

  American Car and Foundry, 121–122

  Amway, 44, 59, 66

  Andry, Doran, 20, 79–80

  AOL, 127

  Apple, 1, 39, 184–188

  buyback of Icahn’s stock, 184, 185, 186–188

  arbitrage, game of, 118, 119

  Auletta, Ken, 115

  Automatic Data Processing Inc., 215

  AXA Center on Seventh Avenue, 76, 78, 89, 111, 158, 159–162

  Bank of England, 134, 139

  bankruptcy, 10, 16, 27, 29, 31, 63, 125, 126

  of Lehman Brothers, 64

  Barbarians at the Gate, The, 126

  Barnes and Noble, 37, 70

  Bartz, Carol, 92

  Bausch and Lomb, 169

  BBC, 162

  Bear Stearns, 11

  Beckham, David, 53

  Benoit, David, 197

  Berkowitz, David, 27–29, 31, 33

  Berkshire Hathaway, 171

  Big Short, The (Lewis), 12

  Biogen, 128

  Boesky, Ivan F., 121, 125–126

  Boies, Schiller firm, 97, 176

  Borders Group, 70–71

  Boston Market restaurant chain, 62

  Botox, 169

  Boyd, Roddy, 173

  Brazil, 58

  Brussels, Belgium, 19, 54

  Buffett, Susan, 27

  Buffett, Warren, 26, 27, 129, 171, 211

  BurnLounge company, 14

  Business Insider, 103, 109, 147

  BuzzFeed News, 213

  Calderon, José, 143

  Canadian Pacific railway, 71, 72, 209

  Carlisle, Tobias, 119

  Carmona, Dr. Richard H., 148

  Celarier, Michelle, 138–139

  celebrity, 7, 9

  Cha
nos, James, 170–171

  Chapman, Brett, 57

  Chapman, Robert, 84–86, 87, 89–90, 100, 150

  Chapman Capital, 84

  Chappaqua, New York, 22–23

  Cheniere Energy, 183–184

  Chesapeake Energy, 183

  Chesebrough-Ponds Inc., 122

  Chipotle chain, 209

  Christodoro, Jonathan, 111, 112

  Chung, Juliet, 100

  Circa Pharmaceuticals, 28

  Citron Research, 174

  Clinton, Hillary, 172, 193

  Clorox, 128

  CNBC, 40, 55, 59, 60, 76, 77–78, 81, 85, 88, 154, 159, 176, 215

  Delivering Alpha conferences, 147, 156–158, 208

  Halftime Report, 101, 103–105, 109, 158

  Squawk Box, 97, 170, 197, 206

  Cohen, Steven A., 111

  commodity prices, 183

  Confidence Game: How a Hedge Fund Manager Called Wall Street’s Bluff (Richard), 12

  consumer activists, 146

  Cook, Tim, 184–188

  corporate raiders, 121

  Corvex Management LP, 113

  Covington & Burling law firm, 32

  Cozza, Keith, 207

  Cramer, Jim, 55

  credit default swaps, 10

  credit ratings, 10, 11, 31

  D.A. Davidson firm, 83, 132

  Day, Andra, 211

  debt, 3, 30, 64, 70, 124, 125, 170, 176, 209

  Deep Value (Carlisle), 119

  De La Merced, Michael, 60–61, 96

  Denis, Mo, 145

  derivatives market, 117, 149

  DeSimone, John, 8, 57, 61, 66, 96, 159–160, 196, 207

  Dewey Square Group, 145

  Dietz, Dr. Park, 6–7

  Dinan, Jamie, 37

  Dinneen, Shane, 15–16, 19–20, 21–22, 72, 74, 76, 78, 80–81, 142

  Disney. See Walt Disney International

  dollars, 163

  Dow Jones Industrial Average, 119

  Dream US, 190

  Drexel firm, 126

  Druckenmiller, Stanley, 134

  Dunton, Gary C., 11

  DuPont, 1

  Durst family 28

  Ebbers, Bernard J., 62

  Edelman, Asher, 113

  Einhorn, David, 37, 58–66, 67–69, 72, 73–74, 201

  out of Herbalife, 69

  Eisman, Steven, 12

  Eisner, Michael, 52

  EM-Tech Co., 137

  energy-drink makers, 141

  Enron, 170, 174, 176

  European Exchange Rate Mechanism (ERM), 134

  Faber, David, 171

  FactSet, 188

  FBI, 132, 155, 167, 180

  FC Barcelona, 53

  Federal Reserve, 156

 

‹ Prev